...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial
【24h】

Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial

机译：5-氟尿嘧啶，亚叶酸和干扰素α-2A治疗晚期胰腺癌：II期试验的结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Interferon alpha-2a (IFN-alpha) and folinic acid (FA) have been shown to modulate the cytotoxic effects of 5-fluorouracil (5-FU) in the treatment of cancer. A phase II study was initiated to evaluate the effect of a combination of 5-FU/FA/IFN-alpha in patients with advanced pancreatic cancer. Sixty previously untreated patients with advanced adenocarcinoma of the pancreas were treated with 500 mg m-2 FU via an intravenous bolus 1 h after the initiation of a 2 h infusion of 500 mg m-2 FA. Before starting the FA infusion, 6 million units (MU) of IFN-alpha was administered subcutaneously. The treatment was repeated once a week. Of 57 evaluable patients, eight (14%) had a partial response (PR), eight (14%) a minor response (MR) and 28 (49%) no change of disease (NC). Thirteen patients (23%) had progressive disease (PD). The median survival time was 10 months for all patients, 22 months for patients with partial remission and 5 months for patients with progressive disease. Many patients with tumour-related pain whose tumours were affected in terms of PR, MR, NC were free of pain during treatment with this regimen (22/36 patients). The common toxicities observed were fever (56%), nausea (37%) and diarrhoea (33%). These data suggest that biochemical modulation of 5-FU with FA and IFN-alpha has some positive effects in the treatment of pancreatic cancer of moderate toxicity.
机译：干扰素α-2a（IFN-α）和亚叶酸（FA）已显示出调节5-氟尿嘧啶（5-FU）在癌症治疗中的细胞毒性作用。开始II期研究以评估5-FU / FA /IFN-α组合对晚期胰腺癌患者的疗效。在开始输注500 mg m-2 FA 2小时后的1小时内，通过静脉推注对60名先前未接受治疗的晚期胰腺癌患者进行了500 mg m-2 FU的治疗。在开始注射FA之前，皮下注射了600万单位（MU）的IFN-α。每周重复一次治疗。在57位可评估的患者中，有8位（14％）有部分缓解（PR），有8位（14％）有轻微缓解（MR），有28位（49％）没有疾病改变（NC）。十三名患者（23％）患有进行性疾病（PD）。所有患者的中位生存时间为10个月，部分缓解患者的中位生存时间为22个月，进行性疾病患者的中位生存时间为5个月。在该方案治疗期间，许多肿瘤相关疼痛的患者的肿瘤在PR，MR，NC方面均无疼痛（22/36位患者）。观察到的常见毒性是发烧（56％），恶心（37％）和腹泻（33％）。这些数据表明用FA和IFN-α对5-FU进行生化调节对中度毒性胰腺癌的治疗具有积极作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号